Azione NRBO NEUROBO PHARMACEUTICALS, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue NeuroBo Pharmaceuticals, Inc.

Azioni

NRBO

US64132R4048

Tempo reale stimato Cboe BZX
Altri mercati azionari
 21:30:30 10/07/2024 		Variaz. 5gg Var. 1 gen.
4,555 USD +0,55% Grafico intraday di NeuroBo Pharmaceuticals, Inc. +3,35% +24,98%
26/06 NeuroBo Pharmaceuticals, Inc. Dosa il primo paziente nella Parte 2 MAD del suo studio clinico di Fase 1 che valuta DA-1726 per il trattamento dell'obesità CI
24/06 NeuroBo Pharmaceuticals annuncia un collocamento privato e un'offerta diretta registrata MT

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
NEUROBO PHARMACEUTICALS DOSES FIRST PATIENT IN THE MAD PART 2 OF ITS PHASE 1 CLINICAL TRIAL EVALUATING DA-1726 FOR THE TREATMENT OF OBESITY
NeuroBo Pharmaceuticals, Inc. Doses First Patient in the MAD Part 2 of its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals Raises $20 Million from Share Placement
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NeuroBo Pharmaceuticals, Inc. announced that it has received $17.000005 million in funding from Dong-A ST Co., Ltd.
NeuroBo Pharmaceuticals Announces Private Placement, Registered Direct Offering
NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NeuroBo Pharmaceuticals, Inc. Announces Pre-Clinical Data
NeuroBo Pharmaceuticals, Inc. Announces Pre-Clinical Data of DA-1241, a Novel G-Protein-Coupled Receptor 119 Agonist, in Combination with Semaglutide
NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone
NeuroBo Pharmaceuticals : Company Presentation May 2024
NeuroBo Pharmaceuticals : Company Presentation May 2024
NEUROBO PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
NEUROBO TO PRESENT LATEST PRE-CLINICAL DATA ON CARDIOMETABOLIC ASSETS, DA-1241 AND DA-1726, TARGETING MASH AND OBESITY, AT SCIENTIFIC CONFERENCES IN JUNE
Sector Update: Health Care Stocks Mixed Wednesday Afternoon
NeuroBo Begins Dosing in Phase 1 Study of Obesity Treatment; Shares Rise
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione NRBO
  4. Notizie NeuroBo Pharmaceuticals, Inc.
  5. Altre lingue